Dr. Nastoupil on Triplet of TGR1202, Ublituximab, and Ibrutinib in CLL

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

This regimen does appear to be tolerated in patients, with most adverse events being grade 1 or 2, says Nastoupil. Infrequent grade 3 events included neutropenia (18%), colitis or diarrhea (3%) and pneumonia at (11%). A maximum tolerated dose has not been determined.

Though the primary endpoint of the study was assessing safety, clinical responses were also reported. The overall response rate was 83%, and was 100% in the CLL cohort, with 6 patients achieving a complete response, Nastoupil adds.